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Summary
Stem cell factor (SCF) is overexpressed by neurons following brain injury as well as by glioma cells; however, its role in glio-
magenesis remains unclear. Here, we demonstrate that SCF directly activates brain microvascular endothelial cells (ECs)
in vitro and induces a potent angiogenic response in vivo. Primary humangliomas express SCF in a grade-dependentmanner
and induce normal neurons to express SCF in brain regions infiltrated by glioma cells, areas that colocalize with prominent
angiogenesis. Downregulation of SCF inhibits tumor-mediated angiogenesis and glioma growth in vivo, whereas over-
expression of SCF is associated with shorter survival in patients with malignant gliomas. Thus, the SCF/c-Kit pathway plays
an important role in tumor- and normal host cell-induced angiogenesis within the brain.Introduction
Malignant gliomas are among the most lethal tumors, with me-
dian survivals of less than a year for patients with the most com-
mon type of glioma, glioblastoma, despite aggressive surgery,
radiation, and chemotherapy. In an attempt to identify novel
therapeutic targets,many investigators have focusedon thepro-
found angiogenic response associated with malignant gliomas
(Plate and Risau, 1995). Tumor-induced angiogenesis is one of
the pathological hallmarks of malignant gliomas and has been
demonstrated experimentally to be important for glioma pro-
gression. Thus, antiangiogenic strategies have great potential
as a treatment approach for gliomas (Stratmann et al., 1997;
Tanaka et al., 1998; Purow and Fine, 2004). Identification of the
most important angiogenic pathways utilized by gliomas is
therefore of interest and significance.
It has been shown that many putative angiogenic factors are
expressed by glioma cell lines in vitro; however, few of these fac-
tors (with the possible exception of vascular endothelial growth
factor [VEGF]), have been conclusively demonstrated to haveCANCER CELL 9, 287–300, APRIL 2006 ª2006 ELSEVIER INC. DOI 10.10any pathophysiological role in glioma progression in vivo (Gold-
brunner et al., 2000; Dunn et al., 2000; Lamszus et al., 2004). This
is important, for it is known that tumor angiogenesis involves
a complex interplay between tumor cells, endothelial cells
(ECs), and other host cells as well as their surrounding extracel-
lular matrix (host stroma) (Liotta et al., 1991; Carmeliet and Jain,
2000; Tlsty andHein, 2001; Kalluri, 2003). Thus, a putative angio-
genic factor may have very different functions in diverse tissue
types and vascular beds. Given the unique microenvironment
and microvascular architecture within the central nervous sys-
tem (CNS), it would therefore not be surprising that various
cytokines might have very different biological effects on the
angiogenic processwithin theCNScompared to that in systemic
capillary beds.
Stem cell factor (SCF) expression has been demonstrated in
the past in a number of glioma cell lines, although its significance
remains unclear. We and others have recently reported that var-
ious formsof brain injury induce neuronal expression of SCF, and
that SCFmediates neural stem cell (NSC) migration to the site of
cerebral injury (Zhang and Fedoroff, 1999; Jin et al., 2002; SunS I G N I F I C A N C E
Tumor angiogenesis is a hallmark ofmalignant gliomas and is thought to play an important role in gliomaprogression. SCF expression in
glioma cells has been reported, but its significance remains unclear. We have nowdemonstrated that SCF expression, both by neurons
aswell as by infiltrating gliomacells, results in amarkedangiogenic response in vivo. Downregulation of SCF expression in vivo results in
improved survival in orthotopic mouse gliomamodels, whereas overexpression of SCF is associated with a worse prognosis in patients
with glioblastoma. This work, therefore, shows that SCF, expressed by both tumor and normal host cells, is an important antiangiogenic
target in malignant gliomas and possibly other SCF-expressing tumors.16/j.ccr.2006.03.003 287
A R T I C L Eet al., 2004; Erlandsson et al., 2004). Likewise, recent data dem-
onstrate that hepatic injury induces SCF production and that
SCF in turn promotes liver regeneration, an angiogenesis-
dependent process (Ren et al., 2003; Greene et al., 2003). Con-
sistent with a potential role in angiogenesis, the SCF receptor
c-Kit is foundoncirculating endothelial precursor cells andhuman
umbilical vein EC (HUVEC) (Broudy et al., 1994; Peichev et al.,
2000; Matsui et al., 2004). We hypothesized that, as an adoptive
response to tumor-induced brain injury, CNS host cell (i.e., neu-
ron)-mediated SCF expression contributes to glioma-derived
SCF expression in inducing a proangiogenic environment within
the CNS that is conducive to tumor progression.
In this study, we demonstrate that SCF is a potent angiogenic
factor in vitro and in vivo. Furthermore, SCF expression is upre-
gulated in gliomas in a grade-dependent manner, and tumor
cells with the strongest SCF expression, as well as normal
SCF-expressing neurons, are found predominantly within the
infiltrating tumor border, an area that colocalizes with prominent
angiogenesis. High SCF expression is associated with shorter
patient survival, and downregulation of SCF expression in gli-
oma cells suppresses glioma-induced angiogenesis and im-
proves survival of the mice bearing intracranial glioma xeno-
grafts. Thus, the SCF/c-Kit pathway plays a prominent role in
pathological angiogenesis within the CNS and may provide
a promising molecular target for glioma treatment.
Results
Aberrant expression of SCF in gliomas
Under normal conditions, little or no SCF expression is detect-
able in the normal brain (Zhang and Fedoroff, 1999; Manova
et al., 1992). To evaluate whether SCF is associated with the
prominent angiogenesis seen in malignant gliomas, we first
determined SCF expression levels in human malignant glioma
cell lines. Quantitative real-time RT-PCR revealed high levels
of both the secreted SCF (sSCF) and membrane bound SCF
(mSCF) mRNA splicing isoforms in all glioma cells examined
(Figure 1A). We further demonstrate by ELISA that high levels
of SCF protein are secreted into the conditioned media (CM)
by glioma cell lines in contrast to very low levels found in the
CM from normal human astrocytes in vitro (Figure 1B). Addition-
ally, lysates of glioma cell lines reveal high levels of SCF protein
as detected by immunoblotting (Figure 1C). The three bands
seen on the Western blot correspond to the sSCF (33 kDa),
cleaved fraction of sSCF (19 kDa), and mSCF (29 kDa).
In order to evaluate the level of SCF expression in primary
human gliomas, rather than in just cell lines, we performed
mRNA expression profiling of 157 primary human gliomas and
23 nontumor human brain samples using the Affymetrix Human
Genome U-133 plus 2.0 GeneChip. A total of four probe sets
corresponding to the SCF gene are present, and Figure 1D dem-
onstrates the data from a typical probe set showing a significant
elevation ofSCFmessage in gliomas in comparison to nontumor
brain (p < 0.001). High-grade gliomas differ significantly from
low-grade gliomas both biologically and genetically. Thus, we
investigated the levels of SCF expression in gliomas of different
grades. The results revealed a statistically significant higher level
of SCF expression in high-grade gliomas (grade III or anaplastic
astrocytoma, n = 31; grade IV astrocytoma or glioblastoma, n =
81) compared to low-grade gliomas (grade II astrocytoma, n =
45) or normal brain (n =23) (p < 0.001) (Figure 1D). Themicroarray288expression data were confirmed by quantitative real-time
RT-PCR demonstrating a significant elevation of SCF in grade
IV gliomas compared to low-grade gliomas or nontumor brain
(p < 0.05) (Figure 1E). Since high-grade gliomas are character-
ized by a much greater amount of tumor-associated angiogene-
sis compared to low-grade gliomas, the positive correlation of
SCF expression with increasing glioma grade is consistent
with a potential role for SCF in glioma-associated angiogenesis.
Effects of SCF on brain microvascular EC
Even though theSCF receptor c-Kit is often expressedon glioma
cells in vitro (Natali et al., 1992; Tada et al., 1994; Stanulla et al.,
1995), even high concentrations of SCF failed to induce prolifer-
ation in our glioma cells in vitro, consistent with previous obser-
vations (data not shown) (Berdel et al., 1992; Stanulla et al.,
1995). Given the lack of effect of SCF on glioma cell growth
in vitro, yet the positive correlation between glioma grade and
higher levels of SCF expression, we reasoned that SCF might
be involved in glioma progression in vivo through some indirect
or paracrine mechanism. To explore the possibility that this indi-
rect effect was a proangiogenic one, we first set out to determine
whether c-Kit was expressed on primary ECs in vitro. All ECs
examined exhibited c-Kit protein on their cell surfaces by FACS
analysis, including bovine brain microvascular EC (BMVEC-b),
HUVEC, and human dermal microvascular EC (HMVEC-d)
(Figure 2A). By contrast, all of seven glioma cell lines demon-
strated the presence of intracytoplasmic but little membrane
bound c-Kit (Figures S1A and S1B in the Supplemental Data
available with this article online; Table S1).
We next exposed BMVEC-b, HUVEC, and HMVEC-d in basal
medium to SCF and determined the rate of thymidine incorpora-
tion at 48 hr or 72 hr. SCF stimulated proliferation in all three pri-
mary ECs in a dose-dependent manner even at low concentra-
tions (i.e., BMVEC-b proliferation increased approximately
6-fold and 7-fold following exposure to 1 ng or 10 ng of SCF
per ml for 72 hr, respectively) (Figure 2B). Additionally, we ex-
posed human brain microvascular EC (HBMEC) to various con-
centrations of SCF (from 0.1 to 10 ng per ml) and demonstrated
a similar dose-dependent pro-proliferative response to that seen
with the BMVEC-b (Figure 2C). It is particularly noteworthy that
SCF alone, without the addition of other cytokines such as
VEGF, was sufficient to sustain human brain microvascular EC
and other EC cell growth and survival.
We next used awound healing assay andMatrigel tube forma-
tion assay to further characterize the effects of SCF on BMVEC-
bmigration and differentiation in vitro. SCF induced a 2- to 3-fold
increase in BMVEC-b migration compared to control in a dose-
dependent manner (Figures 2D and 2E). Additionally, SCF in-
duced BMVEC-b and HBMEC to migrate in Matrigel within 4 hr
of exposure and to form mature appearing capillary-like struc-
tures by 18 hr. By contrast, these primary human and bovine
brain ECs exposed to the vehicle control neither migrated nor
formed capillary-like structures (Figure 2F). In order to establish
whether glioma cells could be exerting a proangiogenic effect on
neighboring ECs throughSCF and other angiogenic proteins, we
evaluated the effects of glioma cell CM on EC proliferation. EC
proliferation increased 5-fold following exposure to glioma CM
compared to basal media. Blocking antibodies to both SCF
and VEGF were able to abolish the mitogenic effects of the
glioma CM on EC proliferation (Figure 2G). These dataCANCER CELL APRIL 2006
A R T I C L EFigure 1. Aberrant expression of SCF in gliomas
A–C: Expressionof the two splicing isoformsof SCF
in human glioma cell lines. A: sSCF and mSCF
were determined by real-time PCR with isoform-
specific probe sets, respectively. B: Secreted
SCF in cell conditioned media was measured us-
ing ELISA and normalized by total protein. C:
Western blot analysis of SCF expression. Tubulin
was used as a loading control. Note that both
SCF isoforms are expressed at higher levels by gli-
oma cells than by normal astrocytes.
D and E: SCF mRNA is overexpressed in primary
human high-grade glioma specimens. D: cDNA
microarray analysis of differential SCF expression
in gliomas according to WHO grades. Note the
positive correlation of SCF expression with in-
creasing grade (grade III and IV gliomas com-
pared to nontumor brain [NB]; **p < 0.001). E: In-
creased SCF mRNA in high-grade gliomas was
confirmed by real-time RT-PCR. Grade II oligo-
dendroglioma (n = 9) and astrocytoma (n = 9);
grade III, anaplastic oligodentrocytoma (n = 8),
anaplastic astrocytoma (n = 9); grade IV (n =
28); NB (n = 9). (*p < 0.05). Relative message indi-
cates the ratio of SCF to b-actin.
Columns and bars show the mean and SEM, re-
spectively.demonstrate the ability of SCF to induce proliferation, migration,
and differentiation of primary brain microvascular ECs in vitro.
SCF/c-Kit activates signal transduction in EC
SCF-mediated c-Kit signaling has been shown to induce activa-
tion of the mitogen-activated protein kinase (MAPKs) and phos-
phoinositide 3-kinase (PI3K)/Akt pathways in known SCF target
cells (Jin, 2005). A recent report suggests that SCF stimulates
a HUVEC angiogenic response through activation of these path-
ways (Matsui et al., 2004).We investigatedwhether SCF could in-
duce these two pathways specifically in primary brain ECs rather
than just in HUVEC. Confluent BMVEC-b and HUVEC cells were
treated with SCF after serum starvation. SCF rapidly induced c-
Kit auto-tyrosine-phosphorylation, which peaked at 10–15 min
and lasted for 30min following exposure (Figure 3A). Additionally,
phosphorylation of MEK1/2, as well as its downstream p44/42
MAPK, was dramatically increased. SAPK/JNK was similarly ac-
tivated 10–15 min following SCF exposure, whereas p38 MAPK
exhibited a prolonged activation for over 30 min.
Like the MAPK pathway, the PI3K pathway was activated fol-
lowing BMVEC-b and HUVEC exposure to SCF. PhosphorylationCANCER CELL APRIL 2006of Akt was significantly enhanced by SCF treatment, which in
turn resulted in phosphorylation of mTOR. Activation of mTOR
increased phosphorylation of 4E-BP1 consistent with a possible
diminished inhibition of 4E-BP1 on eIF4E, which could result in
diminished cap-dependent translation. Thus, SCF activates
the MAPK and PI3K pathways in BMVEC-b in a manner similar
to its effects on HUVEC.
Additionally, SCF (50 ng/ml) induced immediate phosphoryla-
tion of the c-Kit, p44/42 MAPK, and Akt proteins in HBMECs
(Figure 3B). Thus, SCF-induced activation of the MAPK and
PI3K pathways appears to occur in ECs fromboth systemic cap-
illary beds as well as from the brain. In contrast to BMVEC-b,
SCF could not induce phosphorylation of p38 MAPK and
SAPK/JNK in HBMEC (data not shown).Whether this represents
a species-specific difference in SCF-mediated signaling or
reflects different subtypes of ECs from the brain remains to be
determined.
SCF promotes angiogenesis in vivo
We next evaluated whether SCF has proangiogenic activity
in vivo by subcutaneously implanting Matrigel impregnated289
A R T I C L EFigure 2. SCF promotes angiogenesis in vitro
A: c-Kit expression in ECs was determined by FACS in BMVEC-b, HUVEC, and HMVEC-d cells. The blue shaded histograms represent the fluorescence intensity
of c-Kit, and theblack line indicates thecontrol IgG isotype staining. SK-N-SHandNIH3T3 cells were usedas positive andnegative controls, respectively (NIH3T3
not shown).290 CANCER CELL APRIL 2006
A R T I C L Ewith SCF, b-FGF (positive control), or vehicle alone into the adult
SCID mice. Newly formed blood vessels in the Matrigel plugs
were visualized by hematoxylin/eosin (H&E) staining and con-
firmed by immunofluorescent staining for factor VIII-related anti-
gen (vWF)-positive ECs. In addition, Tie2 protein levels in the
Matrigel plugs were determined. Fourteen days after injection,
vehicle control-impregnated Matrigel plugs demonstrated few
vWF-positive vessels and had essentially no detectable Tie2
protein expression (Figure 4). By contrast, SCF (as well as the
positive control b-FGF) induced substantial angiogenesis, as
demonstrated by abundant intact blood vessels as well as high
Tie2 expression within the SCF-containing Matrigel plug. These
data demonstrate that SCF can promote angiogenesis in vivo.
Silencing SCF attenuates glioma angiogenesis
To evaluate the effect of SCF on glioma angiogenesis and pro-
gression, we engineered glioma cells expressing low levels of
SCF by retrovirally transducing an antisense SCF construct or
a SCF shRNA into wild-type U373, U87, and U251 glioma cells
expressing high levels of SCF. The resulting U373 cell line
(U373/as-SCF), U87 cell line (U87/as-SCF), and U251 cell line
(U251/shRNA SCF) were expanded, and then stable low level-
expressing clones were selected by antibiotics and verified by
Western blot (Figure 5A). To avoid the confounding variable of
concurrent VEGF expression, we verified by Western blots that
suppression of SCF expression in our cloned glioma cell lines
had no effects on VEGF expression (Figure 5A). Next, we im-
planted U373/as-SCF or U373/vector cell lines together with
Matrigel subcutaneously into SCID mice in order to assess
glioma-induced angiogenesis in vivo with and without SCF stim-
ulation. Within 2 weeks, a profound angiogenic response was
seen in the Matrigel containing the control U373/vector cells
with multiple vWF-positive perfused vessels and abundant
Tie2 protein in the Matrigel plug homogenates. By contrast, Ma-
trigel containing the U373/as-SCF cells demonstrated far fewer
capillaries with vWF staining and significantly less Tie2 protein in
the plug homogenates (Figures 5B–5D). Thus, suppression of
SCF in glioma cells results in significant inhibition of glioma-
induced angiogenesis in vivo. Consistent with these observa-
tions, U251/as-SCF did not form palpable subcutaneous tumors
several weeks after implantation, in contrast to their matched
U251/vector cells, which formed tumors so large that animals
needed to be euthanized (Figure S2). Likewise, systemically
administered bevacizumab (Genentech, San Francisco, CA)
inhibited U251/vector produced VEGF resulting in profound tu-
mor growth suppression. We could not, however, demonstrate
an additive or synergistic effect of SCF knockdown and VEGF
inhibition, since SCF knockdown alone resulted in complete
tumor growth inhibition (Figure S2).
SCF effects on survival in intracranial tumor model
We next evaluated whether suppression of SCFwould affect the
survival of animals with intracranial gliomas. U373/as-SCF orCANCER CELL APRIL 2006U373/vector cells, U87/as-SCF or U87/vector cells, and U251/
shRNASCForU251/vector cellswere stereotactically implanted
into the cerebral subcortex of adult athymic nu/nu mice. Log-
rank analysis of the Kaplan-Meier survival curves demonstrated
a significant survival advantage for the SCF low-expression
glioma-bearing mice compared to their matched SCF high-
expression parental vector-infected glioma-bearing animals
(p < 0.05) (Figure 6A). Examination of 4-week-old U373/vector
intracranial tumors demonstrated significant SCF expression
within the tumor cells and a robust angiogenic response. By con-
trast, there was significantly lower SCF expression within the
tumor cells of the intracranial U373/as-SCF tumors with an atten-
uated angiogenic response within the tumor (Figure 6B).
Immunohistological staining demonstrated that, although
SCF is generally expressed inmost tumor cells within the central
U373/vector tumor mass, SCF expression was most marked in
tumor cells within the tumor border and in the few infiltrating gli-
oma cells at the invasion front. Increased SCF expression was
also observed in the normal brain tissue adjacent to the tumor
mass (Figure 6C). In situ hybridization for SCF mRNA revealed
that it was the normal host neurons within the cerebral cortex,
adjacent to the invading tumor mass, that accounted for the
non-tumor cell-associated high-level SCF expression (Fig-
ure 6D). Additionally, a similar pattern and level of normal neuro-
nal overexpression of SCF was seen in cortex immediately adja-
cent to U373/as-SCF tumors despite the fact that the actual
tumor cells made very little SCF (in contrast to the U373/vector
cells). Normal neurons at increasingly farther distances from
the tumor site, however, demonstrated progressively less SCF
expression, such that SCF expression was barely detectable
in neurons within the cortex contralateral to the growing tumor
mass (Figure 6E). Together, these results support a role for
tumor cell and normal host neuron-mediated SCF-induced
tumor angiogenesis in glioma progression.
Biological and clinical significance of SCF
in glioma-infiltrated human cerebral cortex
To evaluate whether the patterns of glioma-associated SCF ex-
pression in the intracranialmouse xenograftmodel reflectedpat-
terns seen in human brains with malignant gliomas, we per-
formed extensive immunohistochemical analysis of surgical
specimens from patients with glioblastoma. We observed gen-
erally four important features of the heterogeneous SCF expres-
sion in the brains of patients with glioblastoma. In some areas,
close to the center of tumor mass, very little or no SCF was de-
tected (Figure 7A). SCF was generally expressed at high levels
by glioma cells infiltrating into the cerebral white matter
(Figure 7B). In the glioma-infiltrated cerebral cortex abundant
SCF expression was seen not only in the tumor cells, but also
in normal host neurons (Figure 7C). Thus, therewas profound ex-
pression of SCF in cerebral cortex infiltrated by glioma cells sec-
ondary to both tumor- and normal host neuron-associated SCF
expression (Figure 7D). In summary, SCF expression appears toB: SCF alone sustained EC proliferation and survival as determined by thymidine incorporation.
C: HBMEC also showed dose-dependent growth in the presence of SCF.
D–F: SCF activates brain microvascular ECs. D: In the presence of SCF, BMVEC-b migrated into the denuded zone 18 hr after scraping. Arrows indicate the
wound edge. E: Total cells in denuded zone were counted from three separate fields in each well from triplicates. F: BMVEC-b formed tubular structures on
Matrigel in the presence of SCF but not in controls.
G: The U251-derived CM significantly increased HUVEC proliferation in culture, an effect nearly completely blocked by neutralizing antibodies to either SCF or
VEGF. Scale bar, 200 mM.
Columns and bars show the mean and SEM, respectively.291
A R T I C L Eresidemost prominently in the invasive front of the infiltrating gli-
oma, suggesting its roles in tumor progression. Most notably,
this area of high SCF expression colocalizes with areas of dense
Figure 3. SCF/c-Kit activates MAPKs and Akt pathways in brain microvascu-
lar ECs
Cell lysates were collected at the indicated times after SCF stimulation of
BMVEC-b and HUVEC (A) as well as HBMEC (B) and analyzed by Western
blot with the indicated anti-phosphorylated protein antibodies as well as
anti-total protein antibodies. Arrows: red, phosphorylated protein; blue,
total protein. Tubulin was used as an equal loading control.292microvasculature sprouting and branching, consistent with
a role for SCF in glioma- and normal host neuron-mediated an-
giogenesis (Figure 7E). In addition, abundant c-Kit expression
was also detected on the glioblastoma-associated ECs but little
on the actual tumor cells, consistent with our in vitro data
(Figure 7F). The clinical significance of these findings is reflected
by the fact that patients with glioblastoma (grade IV; n = 64), oth-
erwise matched for known prognostic factors (i.e., age, treat-
ment), who had tumors that expressed high levels of SCF expe-
rienced significantly shorter survival than patients with tumors
expressing relatively low levels of SCF (p = 0.0004 by log-rank
analysis; Figure 7G). By contrast, VEGF expression levels did
not correlate with survival in patients with glioblastoma (p =
0.24).
Discussion
The work reported here describes a role for SCF in tumor-asso-
ciated angiogenesis and specifically in glioma progression. SCF
has been long recognized as an important growth factor for
a number of cell types, including hematopoietic stem cell,
mast cells, melanocytes, and germ cells (Zsebo et al., 1990; Galli
et al., 1992;Mackenzie et al., 1997). In these divergent cell types,
SCF has been shown to have a number of different biological
properties. A role for SCF as a potential angiogenic factor, how-
ever, has not been previously entertained until a recent report
demonstrated itsmitogenic effects on HUVEC cells in vitro (Mat-
sui et al., 2004). We have now expanded on those observations
by demonstrating that SCF has potent mitogen, differentiation,
and chemotactic properties on a variety of primary EC lines
in vitro, and furthermore can induce a robust angiogenic response
and contribute to tumor-associated angiogenesis in vivo.
It has been previously reported that glioma cell lines can ex-
press SCF and c-Kit, implicating SCF as an autocrine growth
factor for gliomas (Hamel and Westphal, 2000). Previous obser-
vations, however, could not demonstrate a mitogenic effect of
SCF on glioma cells. Thus, the role for SCF in glioma pathogen-
esis remained unclear until now. Our data now confirm that SCF
expression is not a direct glioma mitogen but rather a potent gli-
oma-associated angiogenic factor. Although SCF has been pre-
viously implicated in angiogenesis through its ability to regulate
mast cell migration with subsequent release of VEGF (Zhang
et al., 2000), no direct role for SCF in angiogenesis had been pre-
vious described except for a recent report of its ability to induce
HUVEC proliferation and migration in vitro (Matsui et al., 2004).
We have extended those observations by showing that not
only HUVECs, but also primary ECs (including human brain
microvascular ECs) express c-Kit and that SCF-mediated c-Kit
signaling in ECs results in activation of the MAPK and AKT path-
way, leading to enhanced proliferation, survival, andmigration of
ECs even in the absence of VEGF, b-FGF, or other, thought to be
obligate, EC growth factors.
Our data clearly demonstrate the ability of SCF to induce
a potent angiogenic response both subdermally and within the
brain. Furthermore, we show using several different cell lines
and using several different methodologies that downregulation
of SCF expression in an orthotopic glioma model results in di-
minished angiogenesis and prolongation of animal survival. We
believe that these observations have clinical significance based
on our demonstration that the level of SCF expression in primary
human gliomas directly correlates with the grade of the tumorCANCER CELL APRIL 2006
A R T I C L EFigure 4. A high density of blood vessels was induced in SCF- or b-FGF-supplemented Matrigel plugs
A: H&E staining. Scale bars, 500 mM (LP), 50 mM (HP).
B: Immunofluorescence staining for vWF. Scale bars, 100 mM (LP), 50 mM (HP).
C:Westernblot for Tie2 in homogenatesofMatrigel plugs.Arrows: neovasculaturecontaining redbloodcells. LP, lowpower;HP, highpower;M,muscle; S, skin;G,gel.and patient survival. These data demonstrating that high-grade
gliomas express significantly more SCF than low-grade gliomas
or nontumor human brain tissue are fully consistent with the fact
that high-grade gliomas are significantly more angiogenic than
low-grade gliomas. In fact, endothelial proliferation is one of
thepathological criteria for grading agliomahigh grade (Kleihues
and Cavenee, 2000). Additionally, our demonstration of in-
creased angiogenic activity colocalizing with increased SCF
expression in surgical sections of human brains with malignant
gliomas further supports the relevance of SCF-induced angio-
genesis in the pathogenesis of malignant gliomas.
It is becoming increasingly clear that tumorigenesis in vivo in-
volves not just the biology of the tumor cell itself, but rather
a complex interplay between tumor cells and the deregulation
of normal host physiological functions that ultimately aid in tumor
progression (Tlsty and Hein, 2001; Liotta and Kohn, 2001).
Others and we have previously demonstrated that SCF expres-
sion is induced in normal neurons in vivo following various types
of brain trauma (Zhang and Fedoroff, 1999; Sun et al., 2004). Gli-
omas cause significant damage to normal brain parenchyma
through numerous mechanisms including disruption of the
blood-brain barrier with resultant increased cerebral edema
and increased intracranial pressure, glioma-mediated degrada-
tion of the extracellular matrix through overexpression of metal-
loproteases, and release of neurotoxic excitatory moleculesCANCER CELL APRIL 2006such as glutamate (Forsyth et al., 1999; Takano et al., 2001;
VanMeter et al., 2001; Davies, 2002; Chantrain et al., 2004).
Thus, we wondered whether, along with the direct release of
SCF from glioma cells, tumor growth could be eliciting expres-
sion of SCF from normal brain tissue in a manner analogous to
that seen in our brain injury models. Data from both our ortho-
topic model and the surgical sections from human brains with
malignant gliomas demonstrate that normal host neurons within
the area of cerebral cortex, adjacent to the tumor mass and
within the invading front of glioma cells, do express SCF to
very high levels, whereas neurons in areas of cortex away from
the growing tumor do not. These areas of neuronal and glioma
SCF overexpression overlap precisely with areas of sprouting
and branching angiogenesis. Thus, normal host cells within the
brain appear to havebeencoopted to inducepathological angio-
genesis in support of the infiltrating tumor cells. The expression
of SCF by normal host tissue may also help explain why down-
regulation of direct glioma SCF expression through our anti-
sense and siRNAconstructs in our orthotopicmodels decreased
glioma-mediated angiogenesis but did not abolish it and only led
to moderately prolonged animal survival. Full angiogenesis inhi-
bition will likely depend on inhibition of all SCF expression (or
c-Kit inhibition), including both tumor- and normal host neu-
ron-mediated expression, possibly in conjunction with inhibition
of other angiogenic pathways.293
A R T I C L EFigure 5. Suppression of SCF in U373 glioma cells attenuates U373-mediated angiogenesis
A:Downregulation of SCF in U373/as-SCF, U87/as-SCF, andU251/shRNA SCFwas verifiedbyWestern blot. Downregulation of SCF resulted in no effects onVEGF
expression from the cells.
B and C: Immunofluorescence staining for vWF (B) and H&E staining (C) in an in vivo tumor-angiogenesis assay using U373/as-SCF and U373/vector glioma
cells. Scale bars, 100 mM (LP in B), 500 mM (LP in C), 50 mM (HP).
D: Tie2 protein in homogenates of Matrigel plugs (40 mg total protein in each sample) was immunoprecipitated with Tie2 antibody and then detected by
Western blot in duplicate. The comparative quantitative intensities of the amount of Tie2 protein were measured by densitometry. Arrows: neovasculature
containing red blood cells. LP, low power; HP, high power; M, muscle; S, skin; G, gel. Columns and bars show the mean and SEM, respectively.These data strongly implicate SCF as an important angiogenic
factor in pathogenesis ofmalignant gliomas. Among the relatively
large number of factors that have been implicated in glioma-
mediated angiogenesis, the most commonly cited are b-FGF,
PDGF, and VEGF (Dunn et al., 2000; Lamszus et al., 2004).
Although gliomas clearly express b-FGF in a grade-dependent
manner, various studies have failed to find b-FGF receptors on
glioma-associated endothelium, leading some to speculate
that b-FGF is acting more as a glioma autocrine growth factor
rather than an angiogenic factor (Zagzag et al., 1990; Morrison
et al., 1994). The various heterodimer PDGF receptors have
been demonstrated on glioma-associated endothelium; how-
ever, PDGF overexpression tends to occur in low-grade gliomas
and higher-grade gliomas that have transformed from low-grade
gliomas rather than in the more common primary glioblastomas
(Westermark et al., 1995; Ribom et al., 2002; Dai et al., 2001).
Thus, PDGF may also be playing a largely mitogenic autocrine
role in glioma growth and may not have a major angiogenic
function in the majority of high-grade gliomas. VEGF is the one
angiogenic factor that has clearly been implicated in glioma
angiogenesis, as it is highly overexpressed in most high-grade
gliomas and especially in glioblastoma, where its receptor is294overexpressed on glioma-associated endothelium (Berkman
et al., 1993; Hatva et al., 1995). VEGF expression, however, has
been demonstrated to bemost pronounced in glioblastoma cells
adjacent to areas of necrosis, consistent with its known hypoxia
inducibility (Plate et al., 1992; Shweiki et al., 1992). These areas
of necrosis and relative tumor hypoxia, however, are not the
areas of themost pronounced angiogenesis ormost rapid tumor
cell proliferationwithin amalignant glioma. Rather, it is the invad-
ing border of the tumor that harbors the most prominent angio-
genic reaction and tumor cell proliferation (VanMeter et al.,
2001). This is the area that corresponds to the highest SCF
expression.
Our interpretation of these data leads us to believe that SCF,
along with VEGF, may have complementary roles in the robust
angiogenic response seen in malignant gliomas. To date, there
have been a number of clinical trials with small molecule inhibi-
tors of FLK-1 (the VEGF receptor); however, none have yet to
show definitive clinical benefit. Although the lack of clinical suc-
cessmay be secondary to the failings of the individual molecules
tested, it is also plausible to postulate that angiogenic pathways
other than or in addition to VEGFwill need to be targeted for clin-
ical success. As such, SCF may prove to be an importantCANCER CELL APRIL 2006
A R T I C L EFigure 6. Downregulation of SCF expression in glioma cells impedes tumor angiogenesis and prolongs survival in an intracranial tumor model
A: Kaplan-Meier survival curve shows that downregulation of SCF expression in U373/as-SCF, U87/as-SCF, and U251/shRNA SCF tumors significantly improves
survival of tumor-bearing mice compared with their vector controls, respectively (log-rank test p < 0.05).
B: Downregulation of SCF expression attenuates SCF-induced angiogenesis in implanted glioma tumors. In contrast to U373/vector gliomas, the U373/as-SCF
gliomas demonstrate little SCF staining and a markedly lower density of blood vessels. Scale bars, 200 mM (LP); 50 mM (HP).
C: Colocalization of neovasculature with SCF in U373/vector tumors. Tumor tissue shows strong SCF expression and a high density of collapsed vessels (upper
panels).Along the tumor invasionborder (middlepanels), abundant SCF surrounds tumorclusterwithmultiple small vessels in thecenter. Inbrain tissueadjacent
to the tumor mass (lower panels), SCF is expressed both by tumor cells and normal cells within the brain. Scale bar, 50 mM.
DandE: Intracranial tumor induces SCFexpression inaffectedneurons.D: SCF-positive neurons (arrows)are seen in thecerebral cortex infiltratedby tumor (T) as
detected by in situ hybridization using a SCF antisense probe (left). The negative control using a hybridized sense probe is seen on the right. E: SCF-expressing
cells are present in the cerebral cortex close to U373/as-SCF injection (left) as compared to the contralateral side of the brain (right) as analyzed by immuno-
histochemistry. Arrows: red, SCF staining; blue, vWF+ blood vessels. Scale bars, 50 mM.CANCER CELL APRIL 2006 295
A R T I C L EFigure 7. Distribution of SCF expression in human brain harboring a glioblastoma
A–D: SCF-expressingcells by immunohistochemistry in representative regionsofbrainand tumor.A:Center of tumormass.B:Cerebralwhitematter infiltratedby
tumor cells. C: Cerebral cortex with infiltration of tumor cells. D: Cellular tumor adjacent to white matter. Scale bars (shown in D), 100 mM (LP), 50 mM (HP).
E: SCF-expressing tumor cells surrounding newbloodvessels are shownat highermagnification (8003). The toppanels show the SCF-expressing tumor cells (left)
and SCF-negative cells (right) lining blood vessels, respectively. Themiddle and bottompanels show SCF-expressing cells lining the full-length of the blood ves-
sels. Arrowheads indicate cytoplasmic staining of SCF in tumor cells (black), neuron (red), and the boundary between tumor mass (TM) and tumor-infiltrating
whitematter (WM) (green).Note that SCF-expressing tumorcells aremorepronounced in the tumor regionsadjacent tonormalbrainandalong thenewblood
vessels. Scale bars, 25 mM.
F: c-Kit-positive endothelial cells on the glioblastoma-associated vasculature colocalized with CD31-positive endothelial cells (left panels) throughout the tu-
mor, including in areas adjacent to necrosis (N, right panel). Scale bars, 50 mM (left panels), 100 mM (right panel).
G:Kaplan-Meier survival curvedemonstrating survival of patientswith glioblastoma (grade IVgliomas) stratifiedby tumors expressingeither lowor high levels of
SCF (log-rank analyses p = 0.0004) and expressing low or high levels of VEGF (log-rank analyses p = 0.2458).296 CANCER CELL APRIL 2006
A R T I C L Etherapeutic target in high-grade gliomas. There has alreadybeen
one clinical trial of Imatinib (Gleevec), a small molecular inhibitor
of ABL, PDGF, and c-Kit, in patients with malignant gliomas pri-
marily based on the premise of targeting PDGF as an autocrine
growth factor (Kilic et al., 2000; P.Y. Wen et al., 2002, Proc.
Am. Soc. Clin. Oncol., abstract). The investigators in this trial
did not observe any clinical activity from Imatinib; however, the
lack of activitymay havebeen the result of the inability of Imatinib
to cross the BBB. Although it has been argued that one of the
theoretical appeals of antivascular and antiangiogenic therapy
for brain tumors is the nonnecessity for molecules to cross the
BBB, the reality is that many of the endothelial targets may not
be accessible to BBB-impermeable molecules within the blood-
stream if such targets are present on the adluminal side of the
EC. Indeed, given that the BBB works in both directions, a large
protein such as SCF would not easily cross out of the brain back
into the bloodstream. Thus, it is possible that c-Kit expression
may not be expressed on the side of the endothelial cell facing
the blood vessel lumen, thereby making the receptor inaccessi-
ble to BBB-impermeable drugs such as Imatinib. It remains to
be seen whether some of antitumor effects of Imatinib activity
against certain systemic solid tumors, such as gastrointestinal
stromal tumors (GIST), and chronic myelogenous leukemia
(CML) may be in part a result of its antiangiogenic as well as its
direct antitumor effects (Demetri et al., 2002; Kantarjian et al.,
2002; Sawyers et al., 2002).
In conclusion, we have presented data that demonstrate SCF
to be a potent angiogenic factor both in systemic tissue and
within the brain. Additionally, SCF appears to be an important
angiogenic factor in high-grade gliomas, both through direct tu-
mor cell expression of SCF and through the induction of its ex-
pression by normal host neurons within areas of brain infiltrated
by tumor. Normal neuronal expression of SCF in response to
traumatic brain injury also raises the disturbing possibility that
standard invasive procedures such as surgical biopsies or partial
tumor resections may be inducing a proangiogenic response, or
trigger, within the brain. As such, SCF represents a potentially
important therapeutic target for malignant gliomas. Finally, the
ability of normal host neurons to express SCF in response to in-
jury, as well as the potent angiogenic properties of SCF within
the brain, leads one to speculate that SCF may have important
therapeutic potential as a proangiogenic factor in regenerative
tissue repair strategies for various disease states such as stroke
and brain and spinal cord injury as well as neurodegenerative
diseases.
Experimental procedures
Cell culture
Primary ECs (Clonetics, Walkersville, MD) and human astrocytes (Sciencell
Research Laboratories, San Diego, CA) were used at passage 8 or earlier.
HBMEC (Sciencell Research Laboratories) was used at passage 1 or 2. All
malignant glioma cells except for 1321N (Europe collection of cell cultures,
Sigma-Aldrich Corp., St. Louis, MO), bone marrow neuroblastoma cell, SK-
N-SH, and NIH 3T3 were purchased from American Type Culture Collection
(Manassas, VA). All cells were passaged and cultured in conditions recom-
mended by their suppliers.
Thymidine incorporation
After ECs (3 3 103/well) were adhered to 96-well gelatin-coated plates (BD
Discovery Labware, Bedford, MA), the EC growth medium was replaced by
SCF (1.10 ng/ml) (R&D Systems, Minneapolis, MN) suspended in treatment
medium (basal medium with 0.1% BSA) for an additional 48 hr (HUVEC andCANCER CELL APRIL 2006HMVEC-d) or 72 hr (BMVEC-b) with renewal of medium at 24 hr interval.
ECs were cultured for 4 hr in 0.25 mCi of [3H]thymidine (AmershamPharmacia
Biotech, Piscataway, NJ) at the end. High molecular mass [3H]-radioactivity
was precipitated and counted.
EC proliferation
The HBMEC and HUVECwere seeded on 48-well and 24-well plates (poly-L-
lysine-coated plates for HBMEC) at 53 103 or 23 104 per well, respectively.
After cells adhered to thewell (6 hr), growthmediumwas replaced byCM. The
CM collected from U251 glioma cell cultures were pretreated with SCF or
VEGF neutralized antibodies (R&D systems) at the indicated concentrations
for 1 hr at 37ºC before being added to the HUVEC. After 48 hr culture in the
treated media, dead floating cells were washed away, and attached living
cells were trypsinized and counted with hematocytometer.
EC differentiation assay
After the Matrigel (BD Biosciences) formed a solid gel in 24-well plates, se-
rum-starved BMVEC-b cells were seeded on the gel surface at 105 cells
per well and cultured in treatment medium in the presence or absence of SCF
(20 ng/ml). Primary HBMEC were placed on the gel directly at 24 3 103 per
well. Tubular formation was observed using an inverted phase contrast
microscope, and images were captured at 4 and 18 hr after cell seeding.
Each experiment was repeated two or three times.
Wound healing assay
The BMVEC-b (3 3 105/well) was seeded on collagen I-coated plates (24-
well). After cells adhered to the plates (3 hr), growth medium was replaced
by SCF and b-FGF (R&D Systems) or vehicle in treatment medium. After
6 hr of incubation, confluent monolayers of BMVEC-b were wounded with
a pipette tip and incubated in the same condition. The cells were fixed with
4% paraformaldehyde 18 hr after being wounded, and images were cap-
tured. The cells that had migrated across the edge of the wound were
observed microscopically (magnification, 320) and counted in three fields
for eachwell. All assayswere repeated three times in duplicates or triplicates.
Flow cytometry analysis
Cells were incubated with Cy-Chrome conjugated anti-human c-Kit (CD117)
antibody or PE-Cy5 mouse IgG1 as a negative control (BD Pharmingen, San
Diego, CA), respectively. Dead cells were excluded by propidium iodide
staining (Sigma Chemie), and expression of c-Kit on the cell surface was an-
alyzed by FACS (Becton Dickinson, San Jose, CA). For the detection of total
c-Kit including that in the cytosol, permeabilization was performed with BD
cytofix/cytoperm solution (Kit from BD Biosciences) for 15 min prior to the
incubation with c-Kit antibody.
Immunoprecipitation and immunoblotting
Confluent-grown ECs were treated with 50 ng/ml of SCF for 5, 10, 15, and 30
min after 24 hr of serum starvation. The ECs were collected with RIPA lysis
buffer (Upstate, Charlottesville, VA) containing 50 mM NaF, 1 mM Na3VO4,
50 mM PMSF, and Protease Inhibitor Cocktail (Roche). The antibodies were
purchased fromCell Signaling Technology, Inc. (Beverly,MA) or asmentioned
otherwise. All the primary antibodies were used in a 1:1000 dilution except for
the anti-SCF antibody, which was used in a 1:2000 dilution. The primary an-
tibodies were anti-phospho-c-Kit, anti-phospho-MEK1/2 and anti-MEK1/2,
anti-phospho-p44/42 MAPK and anti-p44/42 MAPK, anti-phospho-SAPK/
JNK and anti-SAPK/JNK, anti-phospho-p38 MAPK and anti-p38 MAPK,
anti-phospho-Akt and anti-Akt, anti-phospho-mTOR and anti-mTOR, anti-
phospho-4E-BP1 and anti-4E-BP1, anti-SCF and anti-VEGF (Chemicon, Te-
mecula, CA), and anti-b-tubulin (Sigma). Reblotting was done after mem-
braneswere strippedby reblot kit (Chemicon). Tie2detection inMatrigel plugs
from the in vivo Matrigel assay was carried out by immunoprecipitation and
immunoblotting. The gel plugs were carefully separated from muscle and
skin and homogenizedwith RIPA lysis buffer. The resulting total tissue lysates
(40 mg of protein) were immunoprecipitated with Tie2 antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) and then analyzed by immunoblot with
Tie2 antibody (Zadeh et al., 2004).
ELISA
Cells were seeded at 80% of confluence, and the growth medium was
changed 24 hr later to basal medium containing 0.1% BSA after washing297
A R T I C L Ewith PBS. Forty-eight hours later, the CM were collected, and supernates
were obtained by centrifuge at 2K RPM for 5 min. SCF in the CM was mea-
sured using the human SCF ELISA kit (R&D System) in triplicate following
the protocol provided by themanufactory and normalized by the total protein
levels in the media of each individual sample.
Microarray analysis
All gliomas (grade II, III, and IV) were pathologically diagnosed according to
WHO standard. All tumors and nontumor brain tissues of epilepsy were ob-
tained from surgery patients and frozen immediately after operation (clinical
protocol approvedby theNCI IRBcommitteewith informed consent obtained
from all subjects). The frozen samples were disrupted and homogenized with
TRIZOL (Invitrogen Corp., Carlsbad, CA), and the total RNA isolated from
each sample was further purified using RNeasy Mini Kit (Qiagen, Valencia,
CA). The integrity and quality of the RNA met the quality requirements for
Human Genome U133 Plus 2.0 arrays (Affymetrix, Inc., Santa Clara, CA) rec-
ommended by the company. All experimental procedures for labeling, array
hybridization, and scanning were performed using protocols recommended
by Affymetrix. CEL files were generated by Affymetrix GCOS 1.2 software,
and the present/absent calls were defined with global scaling to target value
of 500. By dChip software (Li andWong, 2001), the CEL files were normalized
to a median-intensity array, and model-based expression values were calcu-
lated using PM/MM difference model. Based on the latest annotation from
Affymetrix NETAFFX service, four probe sets forSCF (KITLG) genewere pres-
ent in each chip. The signal intensities of each probe set were used for ana-
lyzing SCF (KITLG) expressions. The significance in differential SCF (KITLG)
expressions in different grades of gliomas versus human nontumor brains
was determined using log2-transformed expression values by standard un-
paired two-tailed Student’s t test of two groups without assuming equal var-
iance between groups. Themicroarray data have been submitted to theGene
Expression Omnibus (GEO) public database at NCBI, and the accession
number is GSE4290.
Real-time RT-PCR
RNA isolation and cDNA synthesis were performed as described above. A
human probe set covering exon 8 of SCF gene was purchased from Applied
Biosystems (Foster City, CA). Isoform-specific probe sets were selected in
the connecting region of exons 5 and 7 (for mSCF) and in exon 6 (for sSCF)
(Table S1). Two-step real-time PCR was performed in duplicates or tripli-
cates. Data were analyzed on the basis of threshold cycle values of each
sample and normalized with b-actin.
Expression vector and transduction
SCF cDNA was synthesized by RT-PCR and subcloned into the pLenti6/V5-
DEST vector (Invitrogen Corp.) in the antisense orientation following the
supplier’s protocol. The 293FT package cell was cotransfected with the ex-
pression vector and ViralPower Packaging Mixture (Invitrogen Corp.). The
supernatants containing infectious virus particles from transfected 293FT
were used to transduce U373 and U87 glioma cells. The stably transduced
U373 and U87 cell lines were selected with 5 ug/ml of blasticidin for over
2 weeks, and the amount of SCF protein expression was assayed by immu-
noblot. The retroviral expression vector pSM2with the SCF shRNA insert and
the LinX retroviral packaging cells were purchased from Open Biosystems
(Hunstsville, AL). The retrovirus was obtained from plasmid transfected
LinX cells andwas used to transduce U251 cells following themanufacturer’s
protocol. The stable shRNA expression cells were selected with puromycin
at 1 ng/ml for over 2 weeks, and downregulation of SCF was verified by
immunoblot.
In vivo angiogenesis assay and intracranial tumor model
All adult mice (6–8 weeks of age) were from NCI-Fredrick, and the animal
experiments were conducted on an animal experimentation protocol ap-
proved by the NCI’s animal protection committee (the ‘‘ACUC’’). For the
in vivo angiogenesis assay (Capogrossi and Passaniti, 1999), Matrigel with
150 ng of SCF and controls or 53 103 cells was injected into a SCID mouse,
and the plugs with skin and muscle were collected 2 weeks later. For the in-
tracranial implantation of glioma cells, stereotactic surgery was performed
(1mm anterior to the bregma and 2.5mm lateral to themidline) using athymic
nu/nu mice under anesthesia. U373/vector or U373/as-SCF (106 cell) were
suspended in 5 ml of HANK and injected into the caudate nucleus. For298immunohistochemical analysis, mice were sacrificed 4 weeks later, and
brains were carefully recovered after perfusion.
Immunohistochemistry
The fixed brains andMatrigel plugs were prepared for paraffin sectioning and
immunohistochemical analysis. The human GBM tissues were obtained from
surgery patients following the clinical protocol approved by the NCI IRB com-
mittee with informed consent obtained from all subjects. After being deparaf-
finized, the sections were processed for immunohistochemistry with the fol-
lowing primary antibodies: anti-vWF (1:500 dilution), anti-c-Kit (1:200
dilution), anti-CD31 (1:20 dilution), and anti-SCF (1:100 dilution), respectively,
All of the primary antibodies were purchased from Dako Corp. (Carpinteria,
CA) except for the anti-SCF antibody, which was bought from Chemicon. Vi-
sualization of antibody binding was performed by a FITC-conjugated second
antibody (1:500 dilution; Molecular Probes, Eugene, OR) or by the second
antibody tagged with HRP (1:1000 dilution; Dako) following reaction to DAB
(Molecular Probes) or AEC (Sigma).
In situ hybridization
The DIG-labeled probe hybridized to nucleotides 848–895 of the mouse SCF
mRNA sequence (NM_013598 in GenBank) was obtained from GeneDetect
company (Aucklank, New Zealand). After they were deparaffinized, mouse
sections were permeabilized with target retrieval solution (Dako) and hybrid-
ized with sense or antisense DIG-labeled probe at 37ºC for 18 hr. After strin-
gent washing, the hybridized signals were detected by tyramide signal ampli-
fication system and visualized with DAB (Dako).
Statistical analysis
Student’s t test was used to determine statistical significance in compari-
sons. Survival curves were plotted with Kaplan-Meier method and compared
using log-rank test. p < 0.05 was considered significance. Survival trends of
grade IV glioma patients (n = 64) were analyzed relative to SCFmRNA levels.
The actin normalized SCF levels ranging from 0.64- to 10.76-fold were deter-
mined by real-time PCR; levels less than 1.8 were grouped as low SCF, and
those greater than 1.8 were classified as high SCF. In the figures, columns
and bars show the mean and SEM, respectively.
Supplemental data
The Supplemental Data include two supplemental figures and two supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/4/287/DC1/.
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